Sandoz launches Enzeevu in the US
The biosimilar treats retinal diseases including nAMD and DME, and a multi-year private-label agreement will add committed US volumes from mid-2027.
See the latest news and media coverage for Sandoz. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global generic and biosimilar medicines company
sandoz.comLast updated
In short: Sandoz launched Enzeevu in the US and announced a multi-year private-label agreement
The biosimilar treats retinal diseases including nAMD and DME, and a multi-year private-label agreement will add committed US volumes from mid-2027.
Owozy is approved for type-2 diabetes and will be commercialised by local partner Biolab & Co under a distribution agreement.
Biosimilar net sales rise 17% at constant currencies, while full-year net-sales guidance narrows to 5-6% and core-EBITDA margin guidance is upgraded to 23.0-23.5%.
The GLP-1 injection is a generic version of Ozempic for adults with type-2 diabetes, available in three dose strengths via two pen presentations.
Sandoz Group shares dropped after the company issued a more cautious outlook on top-line growth for 2026, citing challenging conditions in Germany and supply constraints...
Sandoz Group AG's 1H 2024 results show non-GAAP EPS of $1.12, $5B revenue (+7% Y/Y), and core EBITDA at $885M.
Basel, October 24, 2023 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced its year-to-date sales for the first nine months...
Spin-off from Novartis successfully completed with first trading day today on SIX Swiss Exchange; Sandoz shares included in key market indices Standalone Sandoz committed to...
Track Sandoz and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Sandoz and other trending companies.